Pluri Inc

PLUR

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Goodman earnings: All eyes on data center progress

Our view after results.
stocks

Earnings Winners: BHP, NAB & TLS lead the pack

The winners of this weeks earnings that saw strong investor backing
stocks

Walmart earnings: Growth in digital buoys margin amid consumer trade-down

We think Walmart stock is significantly overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,303.209.300.10%
CAC 408,455.4456.660.67%
DAX 4025,096.9853.410.21%
Dow JONES (US)49,395.16267.50-0.54%
FTSE 10010,672.5745.530.43%
HKSE26,413.35292.59-1.10%
NASDAQ22,682.7370.91-0.31%
Nikkei 22556,825.70642.13-1.12%
NZX 50 Index13,308.52135.68-1.01%
S&P 5006,861.890.000.00%
S&P/ASX 2009,081.4017.000.19%
SSE Composite Index4,082.0751.95-1.26%

Market Movers